Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
Galera's synthetic enzyme GC4419, appears to stave off severe oral mucositis, a side effect of cancer treatment.
Tandem Diabetes Care launched a new predictive feature for automatically pausing insulin delivery as a free update for its CGM-enabled insulin pumps.
Gene-silencing specialist Sirnaomics has been cleared to start trials of its STP705 drug in bile duct cancer, its first oncology indication.
Tolero Pharmaceuticals has inked a pact to test its CDK9 inhibitor, alvocidib, in combination with AbbVie’s Venclexta in relapsed/refractory AML.
The takeover gives Novo control of a platform that could support development of insulins that respond to glucose.
Gilead CMO quits six months after taking job; Allergan taps Pfizer vet as CMO; and Novartis recruits Siemens ethics chief as it reels from scandal.
The imminent departure leaves Pfenex without a CMO as it gears up to file a new drug application (NDA), although Chen will continue to advise the biotech.
The FDA approved the first generic versions of Mylan’s EpiPen and EpiPen Jr, as shortages of the autoinjectors continue.
Males of soybean cyst nematode, or H. glycines, are able reverse neurodegeneration as part of their natural life cycle.
Biohaven’s new formulation of ALS drug riluzole has helped people with social anxiety face the challenge of speaking in public.